ET-1, a vasoconstrictor peptide originating from endothelial cells, exerts its effects through endothelin receptors and is correlated with cardiovascular disease severity
Dysesthesia (5.1%, 12.3%, 12.5% vs 0.9%) and urinary tract infections (7.5%, 8.8%, 8.4% vs 5.3%) were also noted, although these were generally mild to moderate and most resolved during treatment
Before the FDA restricted the compounding of semaglutide products in 2025 due to a shortage resolution, compounded versions were widely available through telehealth platforms at a fraction of the cost of Ozempic or Wegovy
Fluorescein angiography, where we inject a safe dye and photograph its flow through your retinal blood vessels, helps identify leaking or blocked vessels
With topical GHK-Cu, the risk appears very low